<DOC>
	<DOCNO>NCT01655212</DOCNO>
	<brief_summary>The objective trial investigate whether early treatment oral valganciclovir infant congenital cytomegalovirus infection sensorineural hearing loss prevent progression hearing loss .</brief_summary>
	<brief_title>Congenital Cytomegalovirus : Efficacy Antiviral Treatment Randomized Controlled Trial</brief_title>
	<detailed_description>In Netherlands neonate routinely screen hear first week birth Otoacoustic Emissions ( OAE ) procedure . After second refer Automated Auditory Brainstem Response ( AABR ) perform . The parent newborn , bear ≥ 37 week gestational age , fail AABR Netherlands ( 550 yearly ) ask consent CMV-testing dry blood spot . Newborns diagnose congenital CMV confirm SNHL ( ≥ 20 dB ) eligible inclusion . After informed consent infant randomize age 13 week treatment group ( 6 week valganciclovir 32 mg/kg daily dose ; oral solution ) control group ( antiviral treatment ) . Infants monitor leucopenia liver- kidney function . Inclusion continue least 1.5 year , 25 infant treatment arm randomize . At 1 year follow-up hearing child development assess . Hearing assessed Brainstem Evoked Response Audiometry audiological center . Child development assess home visit Bayley Scales Infant Development III parent fill Dutch Child Development Inventory ( NCDI ) give detailed information communicative development child . Viral load blood urine monitor antiviral treatment well twice control group . This study provide information percentage infant congenital CMV infection fail neonatal hearing screening . The RCT show whether early treatment congenital CMV infect child hear impairment prevents deterioration hearing loss extent . The outcome may lead implementation congenital CMV test neonatal hearing screen program possibly newborn blood screening .</detailed_description>
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Deafness</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Hearing Loss , Sensorineural</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Infants congenital CMV infection hearing loss ( ≥ 20 dB , one ear ) . Age time inclusion &lt; 13 week birth . ≥ 37 week gestational age . Birth weight ≥ 2500 gram . Parental sign informed consent . Indications symptomatic congenital CMV infection base diagnostics carry prior inclusion child trial . In case house visit presence symptomatic CMV infection doubt , inclusion discuss . Depending medical history taking , physical examination laboratory test inclusion decide upon . Treatment antiviral agent immunoglobulin . Leucopenia &lt; 0,5 x 10*9/L ( blood sample test t=0 ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Cytomegalovirus</keyword>
	<keyword>Congenital infection</keyword>
	<keyword>Sensorineural hearing loss</keyword>
	<keyword>Randomized control trial</keyword>
	<keyword>Valganciclovir</keyword>
</DOC>